
AI ‘scribes' in use at Manitoba doctors' offices
'It allows me to be more present with the patient and get more of the patient's issues dealt with in a smaller amount of time,' said Dr. Nichelle Desilets, a family physician in Neepawa.
An 'AI scribe' made both a noticeable dent in her workload and streamlined her workflow on Friday.
The president of Doctors Manitoba said the new technology allowed her to start more appointments on time and treat several walk-ins because she didn't need to do extensive documentation after every visit.
Canada Health Infoway has recruited 400 local primary-care providers to pilot its AI Scribe Program, an initiative involving 10,000 physicians and nurses across the country.
The mandate of the federal government-funded organization is to integrate new technologies into hospitals and other health-care settings to improve productivity and patient outcomes.
Desilets is among those who've signed up for a one-year licence for Empathia AI — marketed as 'a mindful charting assistant — via Infoway.
She has also experimented with Heidi AI and another similar tool that is built into her clinic's electronic medical record system.
Infoway launched a new initiative last month after a review of AI tools to ensure it was only endorsing programs that are aligned with Manitoba's Personal Health Information Act and counterpart legislation from coast to coast.
Spokesman Abhi Kalra said the goal is to use 'ambient technology' to reduce administrative burden in a field where there is a lot of tedious manual labour.
'There is a tremendous amount of productivity to be tapped, safely using AI tools, but it has to be done in a thoughtful manner,' the executive vice-president of connected care said.
AI scribes are creating high-quality, structured summaries of patient visits, he said, noting they are not yet being used to assist with diagnosis or treatment decisions, although that is likely on the horizon.
Doctors Manitoba's 2025 workforce survey found only six per cent of members were actively using an AI scribe as of February.
Seven in 10 of all 1,324 respondents indicated they had tried it at least once or were interested in trying it.
(The response rate for the latest annual membership poll was 39 per cent, which translates into a margin of error of plus or minus two per cent.)
The professional advocacy organization has since created a guide to learn more about the ethical use of AI tools and hosted a webinar that attracted more than 350 attendees in late June.
Earlier this summer, upon arriving at his dermatologist's office, bioethicist Arthur Schafer was asked if he consented to the use of an AI scribe during his appointment.
Patients have the right to opt out, but the founding director of the Centre for Professional and Applied Ethics at the University of Manitoba said he gave it.
Family physician Dr. Nichelle Desilets, president of Doctors Manitoba, in her Neepawa clinic. (Tim Smith / The Brandon Sun files)
'A lot of people will initially feel some unease… because there is a certain amount of technophobia, a certain amount of anxiety about artificial intelligence, generally,' Schafer said.
He recalled there was also initial skepticism when doctors transitioned from pen-and-paper to digital record-keeping.
That pivot has ultimately proven beneficial for patients and health-care professionals alike, Schafer said, noting that poor penmanship caused serious accuracy and communication problems.
Infoway's stakeholder consultations found that early adopters of AI scribes were often unsure about how their data was being used or where it was stored.
Kalra said the absence of formal guidance for the sector and related privacy concerns prompted his team to do a deep dive.
Infoway has purchased 10,000 one-year licences from nine 'pre-qualified vendors' that are headquartered in Canada. They were evaluated on their respective cybersecurity practices and how they support secure data-sharing, among other things.
Wednesdays
A weekly dispatch from the head of the Free Press newsroom.
Schafer said he's optimistic that there is a pilot to assess the benefits and drawbacks of AI tools, and that it's being run by a not-for-profit.
While noting 'the stakes are high' when it comes to protecting confidential health information, he said AI tools have immense potential.
The bioethicist added: 'If we can have the right kinds of safeguards and controls then, potentially, family doctors — of which we have a great shortage in Canada — will be able to see many more patients.'
Doctors Manitoba members who were using AI scribes this winter reported the technology helped them save four to six hours of note-taking per week.
maggie.macintosh@freepress.mb.ca
Maggie MacintoshEducation reporter
Maggie Macintosh reports on education for the Free Press. Originally from Hamilton, Ont., she first reported for the Free Press in 2017. Read more about Maggie.
Funding for the Free Press education reporter comes from the Government of Canada through the Local Journalism Initiative.
Every piece of reporting Maggie produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Winnipeg Free Press
a day ago
- Winnipeg Free Press
AI ‘scribes' in use at Manitoba doctors' offices
Manitoba doctors have started using artificial intelligence-powered note-takers to tune in to appointments and transcribe in real time. 'It allows me to be more present with the patient and get more of the patient's issues dealt with in a smaller amount of time,' said Dr. Nichelle Desilets, a family physician in Neepawa. An 'AI scribe' made both a noticeable dent in her workload and streamlined her workflow on Friday. The president of Doctors Manitoba said the new technology allowed her to start more appointments on time and treat several walk-ins because she didn't need to do extensive documentation after every visit. Canada Health Infoway has recruited 400 local primary-care providers to pilot its AI Scribe Program, an initiative involving 10,000 physicians and nurses across the country. The mandate of the federal government-funded organization is to integrate new technologies into hospitals and other health-care settings to improve productivity and patient outcomes. Desilets is among those who've signed up for a one-year licence for Empathia AI — marketed as 'a mindful charting assistant — via Infoway. She has also experimented with Heidi AI and another similar tool that is built into her clinic's electronic medical record system. Infoway launched a new initiative last month after a review of AI tools to ensure it was only endorsing programs that are aligned with Manitoba's Personal Health Information Act and counterpart legislation from coast to coast. Spokesman Abhi Kalra said the goal is to use 'ambient technology' to reduce administrative burden in a field where there is a lot of tedious manual labour. 'There is a tremendous amount of productivity to be tapped, safely using AI tools, but it has to be done in a thoughtful manner,' the executive vice-president of connected care said. AI scribes are creating high-quality, structured summaries of patient visits, he said, noting they are not yet being used to assist with diagnosis or treatment decisions, although that is likely on the horizon. Doctors Manitoba's 2025 workforce survey found only six per cent of members were actively using an AI scribe as of February. Seven in 10 of all 1,324 respondents indicated they had tried it at least once or were interested in trying it. (The response rate for the latest annual membership poll was 39 per cent, which translates into a margin of error of plus or minus two per cent.) The professional advocacy organization has since created a guide to learn more about the ethical use of AI tools and hosted a webinar that attracted more than 350 attendees in late June. Earlier this summer, upon arriving at his dermatologist's office, bioethicist Arthur Schafer was asked if he consented to the use of an AI scribe during his appointment. Patients have the right to opt out, but the founding director of the Centre for Professional and Applied Ethics at the University of Manitoba said he gave it. Family physician Dr. Nichelle Desilets, president of Doctors Manitoba, in her Neepawa clinic. (Tim Smith / The Brandon Sun files) 'A lot of people will initially feel some unease… because there is a certain amount of technophobia, a certain amount of anxiety about artificial intelligence, generally,' Schafer said. He recalled there was also initial skepticism when doctors transitioned from pen-and-paper to digital record-keeping. That pivot has ultimately proven beneficial for patients and health-care professionals alike, Schafer said, noting that poor penmanship caused serious accuracy and communication problems. Infoway's stakeholder consultations found that early adopters of AI scribes were often unsure about how their data was being used or where it was stored. Kalra said the absence of formal guidance for the sector and related privacy concerns prompted his team to do a deep dive. Infoway has purchased 10,000 one-year licences from nine 'pre-qualified vendors' that are headquartered in Canada. They were evaluated on their respective cybersecurity practices and how they support secure data-sharing, among other things. Wednesdays A weekly dispatch from the head of the Free Press newsroom. Schafer said he's optimistic that there is a pilot to assess the benefits and drawbacks of AI tools, and that it's being run by a not-for-profit. While noting 'the stakes are high' when it comes to protecting confidential health information, he said AI tools have immense potential. The bioethicist added: 'If we can have the right kinds of safeguards and controls then, potentially, family doctors — of which we have a great shortage in Canada — will be able to see many more patients.' Doctors Manitoba members who were using AI scribes this winter reported the technology helped them save four to six hours of note-taking per week. Maggie MacintoshEducation reporter Maggie Macintosh reports on education for the Free Press. Originally from Hamilton, Ont., she first reported for the Free Press in 2017. Read more about Maggie. Funding for the Free Press education reporter comes from the Government of Canada through the Local Journalism Initiative. Every piece of reporting Maggie produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.


Globe and Mail
4 days ago
- Globe and Mail
Maxwell Biosciences Announces AI Department & Hiring of Jon McClure
New leadership to spearhead AI-driven breakthroughs in drug discovery and operational excellence Austin, Texas--(Newsfile Corp. - July 17, 2025) - Maxwell Biosciences ("Maxwell"), a global health technology company pioneering immune-inspired small molecules called Claromers™, today announced new engineering leadership for its Artificial Intelligence efforts—further cementing its decade-long commitment to AI-first innovation. As part of this initiative, the company has appointed Jon McClure as Chief Technology Officer to accelerate the development of its AI-native platform for drug discovery and AI-empowered medical devices. To view an enhanced version of this graphic, please visit: "The future of medicine requires scalable intelligence, and Jon brings exactly that—combined with deeply human values," said Maxwell Biosciences CEO, Founder & Chairman Scotch McClure. "Our AI division will serve as both accelerator and amplifier—driving faster drug design, analyzing clinical trial data and infusing every part of Maxwell with AI." Maxwell is an AI-native organization since its founding in 2016 where intelligent systems are woven into the company's core—designing molecules, modeling human biology and accelerating business operations in real time. Every AI initiative is built with a singular goal: to speed up scientific discovery and translate it into health solutions that create health for the world, safely and affordably. At Maxwell, AI agents act as collaborators. They generate novel Claromer™ structures, predict how those compounds behave in the body and coordinate the tasks needed to move breakthroughs forward. These systems learn continuously, adapt to new data in real-time and operate with the same mission focus as the human teams they work alongside. Inspired by the cooperative logic of immune systems, Maxwell's AI architecture is decentralized, adaptive and deeply aligned with the biology it's helping to transform. The result is a faster, more resilient path from discovery to deployment—designed to meet the global demand for stable, shelf-ready and microbiome-safe anti-infectives. About Jon McClure Jon McClure is a seasoned technology leader with over 20 years of experience in software architecture; systems engineering; and team leadership across biotech, healthcare and gaming sectors. He has led multiple development and DevOps teams managing global high-availability environments. In his last role, he successfully transitioned global infrastructure to a Kubernetes-based architecture to improve scalability and reliability. He directed the nationwide deployment of a mission-critical, HIPAA-compliant patient management system for a major U.S. healthcare network, ensuring operational continuity across more than 150 hospitals during the COVID-19 pandemic. During this time, he also served as the lead engineer on and Jon brings deep expertise in full-stack development, microservices, cloud platforms and DevOps practices to his role as CTO. "Maxwell Biosciences is committed to pioneering the future of medicine through strategic investment in Artificial Intelligence, and I couldn't be more excited to lead that effort," said Maxwell Biosciences CTO, Jon McClure. "AI, when thoughtfully applied, will dramatically accelerate drug discovery, personalize treatment and ultimately create a healthier world. Using my background building high-availability cloud environments and developing large-scale software applications for organizations like the U.S. Department of Veterans Affairs, HHS and BARDA, our focus will be on building robust, AI-driven solutions that address critical challenges in infectious disease and beyond." About Maxwell Biosciences Maxwell Biosciences is a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™. Designed to mimic the body's natural defenses, Claromers™ destroy pathogenic bacteria, viruses, fungi and biofilms—without harming healthy cells or the microbiome. Originally developed for critical infectious diseases, Maxwell's technology is now entering commercial deployment across cosmetics, personal care, medical coatings and biodefense. Claromers™ require no refrigeration and are highly stable in even the harshest environments. Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active partnerships with the US military and governments worldwide. FDA clinical trials are planned for 2026. Non-pharmaceutical commercialization begins in 2025, with pilot access with select partners already underway. Maxwell's AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions for a healthier planet. To learn more about Maxwell Biosciences, visit or follow us on X and LinkedIn.


National Post
5 days ago
- National Post
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Article content BOSTON & SCCT ANNUAL MEETING, MONTREAL — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors. Article content These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, and continues development of its investigational FFR prediction model, based on PlaqueIQ. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. Article content An experienced medical technology executive and clinical expert, Dr. Kuntz is former senior vice president and chief medical and scientific officer of Medtronic plc. Prior to joining Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization that coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration (FDA). Dr. Kuntz has directed several multicenter clinical trials and has authored more than 250 original publications. Dr. Kuntz was an associate professor of Medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston. Article content Dr. Feinglass is a managing director at Manatt Health working across the business, medical, and policy needs of health systems, life sciences, medical device, digital health and diagnostic companies globally. A global leader in health care, Dr. Feinglass has served as an executive and chief medical officer in large multi-national life sciences corporations including Danaher and Zimmer-Biomet. In parallel, she has driven policy changes alongside senior government officials around the world to influence health policy, regulation, and access. A former regulator at U.S. Centers for Medicare and Medicaid Services (CMS) and commander in the U.S. Public Health Service with extensive regulatory and legislative experience, Dr. Feinglass is on faculty at the John's Hopkins Bloomberg School of Public Health, Department of Mental Health and is a member of the Board of Directors of Sandoz AG. Article content 'We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid's Board of Directors,' said Elucid CEO Kelly Huang, PhD. 'Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami's unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.' Article content About Elucid Article content Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Sam Choinski Article content Article content Article content Article content